Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Noonan Syndrome 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Neoplasms 1Lung Diseases 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

selpercatinib 2repotrectinib 1pralsetinib 1pembrolizumab 1osimertinib 1ficlatuzumab 1efineptakin alfa 1cobimetinib 1camrelizumab 1atezolizumab 1apatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thoracic Neoplasms × cobimetinib × Clear all
NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡